Galectin Therapeutics Inc (NASDAQ:GALT)

Data as of Sep 29
 +0.01 / +0.19%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Galectin Therapeutics, Inc. is a development stage company, which is engaged in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Contact Information

Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
P:(678) 620-3186
Investor Relations:



Mutual fund holders6.57%
Other institutional12.83%
Individual stakeholders10.65%

Top Executives

Peter G. TraberPresident, CEO, Director & Chief Medical Officer
Harold H. ShlevinChief Operating Officer & Secretary
Jack W. CallicuttChief Financial Officer
Eliezer ZomerExecutive VP-Manufacturing & Product Development
Rex HortonExecutive Director-Regulatory Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.